Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Conditions
Keywords
non-interventional, Xarelto, knee replacement, hip replecement, Russia
Brief summary
This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in real life thromboprophylaxis is carried out after the discharge from a hospital in the patients who undergo elective knee and hip replacement and who receive Xarelto during hospitalization.
Interventions
DRUGRivaroxaban (Xarelto, BAY59-7939)
The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients ≥ 18 years old * Elective hip or knee replacement * Planned VTE prevention with Xarelto * Written informed consent * The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.
Exclusion criteria
* Contraindications for the use of Xarelto in accordance with the effective instruction * Any reasons of medical and non-medical character, which in the opinion of the physician can hamper participation of the patient in NIS, including a potentially low compliance, impossibility of making the final visit due to distant place of residence of the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real life out-patient thromboprophylaxis after arthroplasty: Share of patients who follow physician's prescriptions; true duration of out-patient thromboprophylaxis; duration of treatment interruptions; in case of switching - reasons, drug regimen. | Not more than 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Descriptive characteristics of prescription behaviour of orthopedists (VTE prevention recommended at discharge): continuation of rivaroxaban, switching to other products (name, dose, duration, efficacy control), mechanical prophylaxis, etc. | Not more than 8 weeks |
| Adverse event characteristics (frequency, severity, relation to VTE prevention treatment, AE treatment, AE outcome) | Not more than 8 weeks |
Countries
Russia
Outcome results
None listed